----item----
version: 1
id: {A1AFF90C-9880-4F51-9961-20ACA9F704EB}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/03/13/FDA accepts BMS resubmitted daclatasvir NDA
parent: {645FC40A-FA7F-499D-A4DF-345C0883A8C0}
name: FDA accepts BMS resubmitted daclatasvir NDA
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 4b44449d-922a-4a8f-a50c-622675c75dc4

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 45

FDA accepts BMS' resubmitted daclatasvir NDA 
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 43

FDA accepts BMS resubmitted daclatasvir NDA
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2718

<p>The FDA has accepted for review Bristol-Myers Squibb's resubmitted new drug application (NDA) for daclatasvir, an investigational NS5A replication complex inhibitor, as a treatment in combination with Gilead's Sovaldi (sofosbuvir) for chronic hepatitis C virus (HCV) in patients with genotype 3, which affects 54.3 million people worldwide.</p><p>BMS said the original NDA was amended to include data from the open-label Phase III ALLY-3 trial, which showed high cure rates for the combination, with sustained virologic response 12 weeks after treatment (SVR12) in 90% of treatment-na&iuml;ve and 86% of treatment-experienced genotype 3 HCV patients. SVR12 rates were higher, at 96%, in non-cirrhotic genotype 3 patients, regardless of treatment history, the company said. </p><p>The FDA will now review the submission within a six-month timeframe.</p><p>Last month, the FDA notified BMS the agency was <a href="http://www.scripintelligence.com/policyregulation/BMS-latest-target-for-breakthrough-status-loss-356576" target="_new">rescinding</a> two breakthrough therapy designations awarded to the regimens related to daclatasvir &ndash; an action the company said was owing to "the &ldquo;evolving HCV treatment landscape."</p><p>Gilead and AbbVie both recently brought new HCV combination drugs to the US market, which have essentially provided a cure for the disease &ndash; <a href="http://www.scripintelligence.com/home/Gilead-combo-HCV-drug-OKd-price-dents-shares-354407" target="_new">Harvoni</a> (ledipasvir-sofosbuvir) and <a href="http://www.scripintelligence.com/home/Viekira-OKd-AbbVie-prices-under-Gileads-Harvoni-355775" target="_new">Viekira Pak</a> (paritaprevir/ritonavir/dasabuvir), respectively. </p><p><b>Related articles:</b></p><p><a href="http://www.scripintelligence.com/policyregulation/BMS-latest-target-for-breakthrough-status-loss-356576" target="_new">BMS latest target for 'breakthrough' status loss</a></p><p><a href="http://www.scripintelligence.com/home/BMS-HCV-drug-daclatasvir-snubbed-by-FDA-355285" target="_new">BMS HCV drug daclatasvir snubbed by FDA</a></p><p><a href="http://www.scripintelligence.com/policyregulation/BMS-seeks-US-OK-for-daclatasvirasunaprevir-in-HCV-351139" target="_new">BMS seeks US OK for daclatasvir/asunaprevir in HCV</a></p><p><a href="http://www.scripintelligence.com/policyregulation/BMS-abandons-breakthrough-HCV-combo-354338" target="_new">BMS abandons 'breakthrough' HCV combo</a></p><p><a href="http://www.scripintelligence.com/policyregulation/BMS-wins-breakthrough-status-for-daclatasvirasunaprevir-dual-regimen-in-HCV-350230" target="_new">BMS wins 'breakthrough' status for daclatasvir/asunaprevir dual regimen in HCV</a></p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 347

<p>The FDA has accepted for review Bristol-Myers Squibb's resubmitted new drug application (NDA) for daclatasvir, an investigational NS5A replication complex inhibitor, as a treatment in combination with Gilead's Sovaldi (sofosbuvir) for chronic hepatitis C virus (HCV) in patients with genotype 3, which affects 54.3 million people worldwide.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 43

FDA accepts BMS resubmitted daclatasvir NDA
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150313T024350
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150313T024350
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150313T024350
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028099
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 45

FDA accepts BMS' resubmitted daclatasvir NDA 
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357181
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042310Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

4b44449d-922a-4a8f-a50c-622675c75dc4
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042310Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
